Supriya Lifescience News and Updates

Name: Latest research reports of Supriya Lifescience Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Supriya Lifescience Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Supriya Lifescience from all sources in a single place.

Supriya Lifescience Ltd.

17 Aug 2026, 12:00AM

877.85

0.33%

Outlook

Accumulate: Supriya Lifescience Ltd.

Target

Deven Choksey

Supriya Lifescience’s growth remains backended to H2 FY27, with management reiterating its INR 1,000 crore revenue target and 33-35% EBITDA margin guidance as Q1 headwinds from solar policy charges and water shortages were temporary.

Supriya Lifescience Ltd. is trading above all available SMAs

Supriya Lifescience Ltd.

14 Aug 2026

877.85

0.33%

to see Rapid results content

Supriya Lifescience Ltd.

06 Jul 2026

877.85

0.33%

Supriya Lifescience tanks 12%; why pharma stock under pressure?

Business Standard

Supriya Lifescience said proceedings were initiated against the personnel of the company under the NDPS Act, 1985 for a procedural lapse for a single export transaction of an identified producer.

Supriya Lifescience has gained 52.17% in the last 6 Months

Supriya Lifescience Ltd.

09 Jun 2026

877.85

0.33%

Product Diversification and Manufacturing Expansion Strengthen Growth Visibility

Accumulate: Supriya Lifescience Ltd.

Target

Deven Choksey

Supriya Lifescience is evolving from a niche anesthetic API player into a diversified specialty API company with multiple growth engines.

Supriya Lifescience has gained 36.24% in the last 1 Year

Supriya Lifescience Ltd.

29 May 2026

877.85

0.33%

to see Rapid results content

Supriya Lifescience Ltd.

29 May 2026

877.85

0.33%

Supriya Lifescience up 15% on healthy Q4 results; should you buy or hold?

Business Standard

The company's management said improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the financial year 2025-26.

Supriya Lifescience has gained 52.17% in the last 6 Months

Supriya Lifescience Ltd.

10 Feb 2026

877.85

0.33%

to see Rapid results content

Supriya Lifescience Ltd.

18 Nov 2025

877.85

0.33%

Strong sequential rebound with broad-based growth; exports and Module E ramp-up drive performance

Accumulate: Supriya Lifescience Ltd.

Recommendation Target

Deven Choksey

We expect growth momentum to sustain over the coming quarters, supported by steady demand across regulated markets, scale-up of the Module E facility, and a stronger mix from high-value therapies.

Supriya Lifescience has gained 52.17% in the last 6 Months

Supriya Lifescience Ltd.

01 Sep 2025

877.85

0.33%

Supriya Lifescience Eyes 33-35% Ebitda Margins In FY26 Led By New Products, US Expansion

NDTV Profit

The company has already launched a new anaesthetic product in the first quarter of FY26, targeting a $300 million market.

Supriya Lifescience has gained 52.17% in the last 6 Months

Supriya Lifescience Ltd.

22 Aug 2025

877.85

0.33%

Short-term weakness; robust pipeline supports outlook

Buy: Supriya Lifescience Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -3.8%/+0.3% primarily to reflect miss in the Q1FY26 performance, and higher depreciation expenses, however, FY27 numbers are intact with rising regulated market share, enhanced backward integration, scale-up of the DSM contract, and new launches such as contrast media and ADHD APIs.